MedTrace Logo

The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients

NCT02747979 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-04-26

No results posted yet for this study

Summary

A prospective, randomized, controlled open clinic trial to evaluate the effect and safety of combination of conventional hemodialysis(HD) and hemoperfusion(HP) on middle molecules removal and complications improvement in long-term maintenance hemodialysis (MHD) patients.

There are two phases of study for each subject. Phase 1 (screening phase). During this phase, each potential subject will be evaluated to determine if he/she is eligible for the study.

Phase 2 (intervention phase). Each subject will be randomly allocated to HD+HP(HA130 once per week) group ,HD+HP(HA330 once per week) group and HD group. The follow-up duration was 3 months.

Conditions

  • Hyperparathyroidism
  • Refractory Pruritus
  • Ostalgia
  • Insomnia

Interventions

OTHER

hemodialysis only

hemodialysis treatment only

OTHER

hemodialysis plus hemoperfusion(HA330)

combination of hemodialysis and hemoperfusion (HA330) treatment

OTHER

hemodialysis plus hemoperfusion(HA130)

combination of hemodialysis and hemoperfusion (HA130) treatment

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Xueqing Yu, MD · Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University

  • Zhihua Zheng, MD · Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University

  • Xunhua Zheng, master · Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02747979 on ClinicalTrials.gov